The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Source: Dr. Douglas Loe (04/14/2025)

In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.

Four-Year Data on New Drug for Early AD Positive
Source: Dr. Ram Selvaraju (04/09/2025)

Long-term treatment with this small molecule seems feasible given its safety and tolerability profile, noted an H.C. Wainwright & Co. report.

Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Source: Jason Kolbert (04/09/2025)

These anticipated events will advance the oncology firm's lead candidate, for lung-only metastatic osteosarcoma, toward commercialization, noted a D. Boral Capital report.

New Drug for Early AD Shown to be Efficacious, Safe
Source: Jason Kolbert (04/09/2025)

Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report.

Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal
Source: Streetwise Reports (04/08/2025)

Beam Therapeutics Inc. (BEAM:NASDAQ) shows strong momentum with positive analyst ratings and new data from its BEAM-302 trial in AATD. Find out why experts see major upside potential.